Innovations in Haematology Cell Therapy at ASH ...

By HEOR Staff Writer

December 5, 2025

Advancing Haematology Cell Therapy Innovations at ASH 2025 AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th America...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Accelerating Access to Latin America Innovative Therapies Through Collaborati...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line The...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...